# Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma

> **NCT00253630** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 37 (actual)

## Conditions studied

- Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
- Nodal Marginal Zone Lymphoma
- Recurrent Grade 1 Follicular Lymphoma
- Recurrent Grade 2 Follicular Lymphoma
- Recurrent Grade 3 Follicular Lymphoma
- Recurrent Mantle Cell Lymphoma
- Recurrent Marginal Zone Lymphoma

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Vorinostat

## Key facts

- **NCT ID:** NCT00253630
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2016-05
- **Final completion:** 2016-05
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2018-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00253630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00253630, "Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00253630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*